Select Medical Holdings Corporation (NYSE: SEM) entered into a definitive merger agreement on March 2 2026 with a consortium headed by Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and private‑equity firm Welsh, Carson, Anderson & Stowe (WCAS). The consortium will purchase all outstanding shares not already owned for $16.50 in cash per share, valuing the company at an enterprise value of roughly $3.9 billion. The offer represents an 18% premium to the 52‑week high and a 25% premium to the 90‑day volume‑weighted average closing price as of November 24 2025.
Select Medical will remain a privately held entity after the transaction, with its existing management team retained to oversee operations. The deal preserves the company’s current debt load, allowing the new owners to focus on long‑term strategic initiatives without the pressure of quarterly earnings disclosure.
Select Medical operates 104 critical‑illness recovery hospitals, 38 rehabilitation hospitals, and 1,917 outpatient rehabilitation clinics across 39 states and the District of Columbia. The company’s most recent financials show a long‑term decline in gross and operating margins, with a current gross margin of 11.54% and an operating margin of 6.17%. Its debt‑to‑equity ratio stands at 1.68, indicating a moderate leverage profile.
In the fourth quarter of 2025, Select Medical reported revenue of $1.4 billion, surpassing analyst expectations by $40 million, while earnings per share of $0.16 fell short of the $0.23 consensus. The revenue beat was driven by strong demand in core post‑acute care segments, offsetting pressure in legacy services, whereas the EPS miss reflected higher operating costs and margin compression in certain service lines.
The market reacted positively to the announcement, largely because the premium offered is substantial relative to recent price levels and the transaction was approved unanimously by the board and a special committee of independent directors. Investors viewed the deal as a way to unlock value and provide the company with greater strategic flexibility away from public‑market scrutiny.
The transaction is expected to close in mid‑2026, contingent on customary regulatory approvals and shareholder consent. The consortium’s leadership structure, which includes key executives from Select Medical and a seasoned private‑equity partner, signals confidence in the company’s long‑term growth prospects under a private‑ownership model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.